Lupus & antiphospholipid syndrome
Clinical utility and performance of anti-C1q antibodies for SLE: comparative analysis of three different assays
Authors' conclusion
Anti-C1q can identify patients with SLE and correlate with global and renal disease activity, highlighting their potential to function as follow-up markers in SLE. Agreement with commercial anti-C1q kits is variable.
Study context
- Population
- Unselected cohort of patients with suspicion of a systemic autoimmune disease (classified as SLE or mimicker) and controls107 patients and 102 controls
- Exposure
- Three anti-C1q kits
- Outcome
- Diagnostic performance of each anti-C1q kit
Methodological detailsdiagnostic performance comparison of three commercial kits
- Diagnostic performance comparison of three commercial kits
Main finding
As reported in the abstract
SLE vs non-SLE discrimination (AUC)
| Group | AUC |
|---|---|
| Werfen | 0.76 |
Werfen
AUC0.76
Observational data: associations, not effects.
Further findings
| Outcome | Bühlmann | Orgentec | Werfen |
|---|---|---|---|
| SLE vs mimicker discrimination (AUC) | |||
| AUC | 0.71 | — not stated in the abstract | 0.71 |
| Active LN vs non-active LN (AUC) | |||
| AUC | — not stated in the abstract | 0.74 | — not stated in the abstract |
— not stated in the abstract
History of lupus nephritis (LN) vs non-renal SLE
- All kits exhibited poor discrimination
Correlation of anti-C1q with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and complement
- Positive correlation with SLEDAI scores; negative correlation with C3 and C4 across all kits
Between-kit agreement for SLE (Fleiss Ƙ)
- Moderate agreement between the three kits (Ƙ)
- 0.42
Original publication
Clinical utility and performance of anti-C1q antibodies for SLE: comparative analysis of three different assays. Lupus Sci Med. Published 6 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →